Target intelligence / Profile preview

DNA polymerase alpha (POLA) (POLA)

Target
POLA
Molecular classification
Enzyme, DNA-directed DNA polymerase, Transferase
01

Overview

DNA polymerase alpha (POLA) is a critical enzyme complex in eukaryotic cells responsible for initiating DNA replication by synthesizing RNA-DNA primers. It plays a fundamental role in the S phase of the cell cycle, ensuring the accurate duplication of the host genome. In clinical pharmacology, host DNA polymerases are significant off-targets for nucleoside analog antivirals like ganciclovir. Ganciclovir is converted by viral and host kinases into ganciclovir triphosphate (GCV-TP), which structurally resembles deoxyguanosine triphosphate (dGTP). GCV-TP competitively inhibits the incorporation of dGTP into the growing DNA strand by host DNA polymerase alpha, albeit with lower affinity than for viral polymerases (PubChem CID 3454). This inhibition leads to the slowing or termination of DNA chain elongation, which can halt cell division in rapidly proliferating host tissues. The primary clinical consequence of this interaction is myelosuppression, manifesting as severe neutropenia, anemia, and thrombocytopenia (StatPearls NBK554403). Because of this off-target effect, ganciclovir has a narrow therapeutic index and requires close monitoring of hematologic parameters (DrugBank DB00449).

Other names
DNA-directed DNA polymerase alphaHost cellular DNA polymerasePOLA1DNA polymerase alpha catalytic subunitDNA polymerase alpha complex
02

Mechanism of action

Competitive inhibition of deoxyguanosine triphosphate (dGTP) incorporation into DNA, leading to DNA chain termination or slowing of elongation.

03

Biological functions

DNA replicationDNA repairRNA-DNA primer synthesisCell cycle progression
04

Disease associations

InfectionCancerCytomegalovirus infectionBone marrow failure
05

Safety considerations

MyelosuppressionNeutropeniaThrombocytopeniaAnemiaTeratogenicityInhibition of spermatogenesisMutagenicity
06

Interacting drugs

Ganciclovir

4 more in the full profile.

07

Biomarkers

Absolute neutrophil countPlatelet countHemoglobinSerum creatinine

Beyond the preview

Go deeper on DNA polymerase alpha (POLA) (POLA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA polymerase alpha (POLA) (POLA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call